Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03491683 · ClinicalTrials.gov registry record · Phase 1

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

A Phase 1 study of Glioblastoma, sponsored by Inovio Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
52
Enrollment target
20
Study locations

NCT03491683 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by Inovio Pharmaceuticals. The registered enrollment target is 52 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03491683, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by Inovio Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
52 participants
Enrollment target
20
Study locations

Study Summary

Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).

Conditions Studied

Glioblastoma

Interventions

  • RADIATION Radiation Therapy
  • DRUG Temozolomide
  • BIOLOGICAL Cemiplimab
  • BIOLOGICAL INO-5401
  • BIOLOGICAL INO-9012

Study Locations (20)

New York

  • New York University Langone Medical Center; Perlmutter Cancer Center - New York
  • Icahn School of Medicine at Mount Sinai - New York
  • Columbia University Medical Center The Neurological Institute of New York - New York
  • New York-Presbyterian Hospital/Weill Cornell Medical Center - New York

California

  • City of Hope - Duarte
  • Stanford University, School of Medicine - Palo Alto
  • University of California, San Francisco - San Francisco

Florida

  • University of Miami - Sylvester Comprehensive Cancer Center - Miami
  • Moffitt Cancer Center - Tampa

Pennsylvania

  • University of Pennsylvania Health System: Penn Medicine - Philadelphia
  • UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion - Pittsburgh

Texas

  • Texas Oncology - Austin
  • Baylor College of Medicine - Houston

Georgia

  • Emory University School of Medicine - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • Henry Ford Health System - Detroit

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2018-05-31
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Inovio Pharmaceuticals

28 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03491683

The ClinicalTrials.gov registry entry for NCT03491683 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (52% lower). The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Radiation Therapy is the first listed.

NCT03491683 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, California, Florida.

Frequently Asked Questions

What is clinical trial NCT03491683 about?

NCT03491683 is a clinical study titled "INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)". Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).

What is the current status of trial NCT03491683?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2018-05-31. Estimated completion is 2026-12-31.

What conditions does trial NCT03491683 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT03491683?

The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Cemiplimab (BIOLOGICAL), INO-5401 (BIOLOGICAL), INO-9012 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03491683?

This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03491683 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.